middle.news
Alterity Therapeutics Revamps Board to Propel Phase 3 Clinical Push
9:29am on Friday 21st of November, 2025 AEDT
•
Healthcare
Read Story
Alterity Therapeutics Revamps Board to Propel Phase 3 Clinical Push
9:29am on Friday 21st of November, 2025 AEDT
Key Points
Founding chairman Geoffrey Kempler retires after over 20 years
Long-serving director Brian Meltzer also steps down
CEO Dr David Stamler appointed Managing Director and CEO
Julian Barbaczy joins as Non-Executive Chair bringing finance expertise
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE